

RECEIVED
CENTRAL FAX CENTER

NOV 22 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of Prina Fishman
Serial No. 09/700,751 Group Art Unit: 1623.
Filed: January 4, 2001 Examiner: J. Young
For: PHARMACEUTICAL COMPOSITIONS COMPRISING AN
ADENOSINE..

DECLARATION
under Rule 132

Commissioner of Patents and Trademarks
Washington, D.C. 20231

I, Ad P. IJzerman, a Dutch citizen residing at Park
Oosterspaarn 6, 2036MB Haarlem, The Netherlands, hereby
declare:

1. I am the same Dr. IJzerman, who made the Declaration
of June 29, 2004.
2. I was requested by Can-Fite BioPharma Ltd. to review
a Study Report prepared by the French company Cerep
(Study Number 8842). The purpose of this Study, as
indicated on page 4 of the Report "was to investigate
the effects of 6-(γ,γ -dimethylallylamino)purine riboside
in the in vitro human adenosine receptor binding
assays". This is the same compound identified as IPA in
the manuscript of the Mittelman et al. reference
(Annals New York Academy of Sciences, Vol. 255, pp.
225-234, 1975), to which I referred in my
aforementioned previous Declaration. For the sake of
consistency, I will refer to this compound herein as
IPA.
3. The binding affinity of IPA to the A3 adenosine
receptor, as summarized in Table 1 - .1 on page 9 of the
Report, is 51 nM. The binding affinity of IPA to the A1
adenosine receptor is 100 nM.

0129355468-01

4. This result suggests that IPA is not a selective A3 adenosine receptor agonist. There is a two-fold difference between the binding affinity of IPA to the A1 and A3 adenosine receptors but such a two-fold difference, when attained in such assays, is regarded as irrelevant.

5. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: November 15, 2004



Dr. Adam J. Zerman

01293354/68-01